Clinical Trials

For patients and health care providers who are interested in learning more about our ongoing clinical trials, please contact the Otonomy Clinical Trial Information group by phone at 1-844-OTO-INFO (1-844-686-4636), or by email at clinicaltrials@otonomy.com.

Here is a listing of company-sponsored clinical trials with their corresponding details.

Drug / Drug Candidate Trial Description Disease Type Trial Status
Otividex
(OTO-104)
U.S. Phase 3 Trial (AVERTS-1): Randomized, double-blind, placebo-controlled trial of OTO-104 given as a single intratympanic injection in subjects with Meniere’s disease
View Website »
Meniere’s disease Active, Not Recruiting
Otividex
(OTO-104)
EU Phase 3 Trial (AVERTS-2): Randomized, double-blind, placebo-controlled trial of OTO-104 given as a single intratympanic injection in subjects with Meniere’s disease
View Website »
Meniere’s disease Recruiting
Otividex
(OTO-104)
Phase 2 Trial: Open label study of OTO-104 given at 3 month intervals by intratympanic injection in subjects with Meniere’s disease
View Website »
Meniere’s disease Active, Not Recruiting
Otividex
(OTO-104)
Phase 2 Trial: Randomized study to assess the feasibility, safety, and efficacy of OTO-104 in subjects at risk for cisplatin-induced hearing loss
View Website »
Cisplatin Induced Hearing Loss (CIHL) Recruiting